Marstacimab in Patients with Hemophilia A or B
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.
QUINCY, MA, May 1, 2024—The National Organization for Rare Disorders (NORD) announced today that Pamela K. Gavin has been named CEO effective immediately. She
Treatment with NALL for 12 weeks yields better neurological status than placebo among patients with Niemann-Pick disease type C.
Cat Lutz, PhD, MBA, VP at JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases.
Philips has reached a $1 billion settlement in the U.S. related its Respironics ventilators, and backed its full-year guidance.
Bill Grambley explains how his company attacks health inequalities by providing personalized pharmaceutical care with an AI based platform.
We have noticed an unusual activity from your IP 192.133.77.15 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.181 and blocked access to this
There are a total of 12 candidates in mid to late-stage trials for ALS poised to enter the market in the next five years.
From the original Broadway production of “Camelot” ; together with the song is a slideshow of several photos of the production starring Julie Andrews, Richar…
Tambourine is a private grantmaking foundation founded by Ben Silbermann and his wife Divya Silbermann. Ben Silbermann is a billionaire donor and former technology executive…